1-[1-[[(1,1-Dimethylethyl)amino]methyl]-2-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]ethyl] (2Z)-2-butenedioate | 1160826-32-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-[1-[[(1,1-Dimethylethyl)amino]methyl]-2-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]ethyl] (2Z)-2-butenedioate
• 英文别名: (Z)-4-[1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-yl]oxy-4-oxobut-2-enoic acid
• CAS: 1160826-32-3
• 化学式: C₁₇H₂₆N₄O₆S
• 分子量: 414.5
• InChiKey: MGIAXRFZDNBKRF-PLNGDYQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  151
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• [EN] DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：GRAYBUG VISION INC

  公开号：WO2018175922A1

  公开（公告）日：2018-09-27

  The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

  本发明提供了治疗活性化合物的新前药，包括寡聚前药，以及用于治疗医学疾病的组合物，例如青光眼，一种与眼压增高有关的疾病或异常，需要神经保护的疾病，年龄相关性黄斑变性，或糖尿病性视网膜病变。
• Process for preparing R-(+)-3-morpholino-4-(3- tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole
  申请人：FAN Chin-Tsai

  公开号：US20110092507A1

  公开（公告）日：2011-04-21

  The present invention provides a process for preparing optically active timolol. The process comprises the following steps. Firstly, reacting 3-hydroxy-4-morpholino-1,2,5-thiadiazole with an optically active epichlorohydrin in the presence of a solvent system, which has a first volume and a catalyst optionally in the presence of a suitable base to obtain an optically active intermediate product. Secondly, treating the optically active intermediate product with a solution, which has a second volume and comprises tert-butylamine to obtain an optically active timolol. The solvent system used in the first step can be an amide solvent, sulfoxide solvent, cyclic hydrocarbon solvent, ketone solvent, or a heterocyclic solvent. The catalyst used in the first step can be an alkali metal hydroxide, alkali metal carbonate, alkali metal hydrogen carbonate, piperidine, pyridine, triethylamine, potassium hydroxide, sodium hydroxide, potassium carbonate, and other heterocyclic bases.

  本发明提供了一种制备光学活性的缬草定的方法。该方法包括以下步骤：首先，在溶剂体系和催化剂的存在下，反应3-羟基-4-吗啉基-1,2,5-噻二唑与光学活性环氧氯丙烷，所述溶剂体系具有第一体积并且可选地在适当碱的存在下，以获得光学活性中间产物。其次，用含有叔丁基胺的溶液（具有第二体积）处理光学活性中间产物，以获得光学活性缬草定。在第一步中使用的溶剂体系可以是酰胺溶剂、亚砜溶剂、环烃溶剂、酮溶剂或杂环溶剂。在第一步中使用的催化剂可以是碱金属氢氧化物、碱金属碳酸盐、碱金属氢碳酸盐、吡啶、吡啶、三乙胺、氢氧化钾、氢氧化钠、碳酸钾和其他杂环碱。
• Ophthalmic preparations comprising timolol maleate
  申请人：CHATFIELD PHARMACEUTICALS LIMITED

  公开号：EP0448856A1

  公开（公告）日：1991-10-02

  An ophthalmic preparation in uni-dose form comprises an aqueous solution of timolol maleate in the absence of any buffering agent or preservative. It may contain sodium chloride to increase the tonicity of the solution or make it isotonic, and may further contain sodium hydroxide to adjust the pH to the range 6.5 to 7.5. Preferably the preparation is supplied in plastics containers formed by the blow-fill-seal process, each container containing 0.1 to 0.3 ml of solution and 0.001 to 5.0 mg of timolol maleate.

  单剂量眼用制剂包括马来酸噻吗洛尔水溶液，不含任何缓冲剂或防腐剂。其中可能含有氯化钠，以增加溶液的补液性或使其等渗，还可能含有氢氧化钠，以将 pH 值调节到 6.5 至 7.5 之间。制剂最好装在由吹塑-灌装-密封工艺形成的塑料容器中，每个容器中含有 0.1 至 0.3 毫升溶液和 0.001 至 5.0 毫克马来酸噻吗洛尔。
• [EN] AGENT FOR TREATING PROSTATIC HYPERPLASIA
  申请人：SEINFELD, Hugo

  公开号：WO1990007927A1

  公开（公告）日：1990-07-26

  (DE) Verwendung von $g(b)-Rezeptorenblockern, insbesondere von 1-[(1,1-Dimethylethyl)amino]-3-[(4-morpholinyl-1,2,5-thiadiazol-3-yl)oxy]-2-propanol-maleat bei der Behandlung von Hyperplasien der Prostata.(EN) Use of $g(b)-receptor blockers, in particular 1-[(1,1-dimethylethyl)amino]-3-[(4-morpholinyl-1,2,5-thiadiazol-3-yl)oxy]-2-propyl alcohol-maleate, for treating prostatic hyperplasia.(FR) Utilisation de substances blocantes des récepteurs $g(b), en particulier 1-[(1,1-diméthyléthyl)amino]-3-[(morpholynil-1,2,5-thiadiazol-3-yl)oxy]-2-propanol-maléate, pour le traitement de l'hypertrophie de la prostate.

  应用 $g(b)$ 再受体阻滞剂，特别是 $1$-[(1,1-甲基乙基)氨基] $3$-[(4-morpholinyle-1,2,5-噻宰-3-yl)oxy]-2-丙醇-肉桂酸酐酯，用于治疗前列腺增生。
• ANTITHROMBOTIC ORGANIC NITRATES
  申请人：NICOX S.A.

  公开号：EP0941218B1

  公开（公告）日：2002-10-16